SERPINB5 and neoplasm: The RFS of the 24 patients with maspin-overexpressing tumours (5-year RFS 41.8±10.5%) was shorter than that of the 48 patients whose tumours normally expressed maspin (5-year RFS 84.4±5.4%) and also shorter than that of the 33 patients with maspin-underexpressing tumours (5-year RFS 83.6±6.7%).